{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:19:13Z","timestamp":1787530753838,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Plan of Jiangxi Provincial Health Commission","award":["202311525"],"award-info":[{"award-number":["202311525"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"DOI":"10.1186\/s13019-026-04418-w","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:04:23Z","timestamp":1781539463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction of PANoptosis-related lncRNA prognostic model and immunotherapy sensitivity analysis in lung adenocarcinoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Xiang","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"4418_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-00983-w","author":"Y Liu","year":"2022","unstructured":"Liu Y, et al. circ_0004140 promotes LUAD tumor progression and immune resistance through circ_0004140\/miR-1184\/CCL22 axis. Cell Death Discovery. 2022. https:\/\/doi.org\/10.1038\/s41420-022-00983-w.","journal-title":"Cell Death Discovery"},{"key":"4418_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030384","author":"M Spella","year":"2021","unstructured":"Spella M, Stathopoulos GT. immune resistance in lung adenocarcinoma. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13030384.","journal-title":"Cancers"},{"key":"4418_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.925618","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, et al. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in hepatocellular carcinoma. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.925618.","journal-title":"Front Immunol"},{"key":"4418_CR4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/cns.13654","volume":"27","author":"RJ Wan","year":"2021","unstructured":"Wan RJ, Peng W, Xia QX, Zhou HH, Mao XY. Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma. CNS Neurosci Ther. 2021;27:973\u201386. https:\/\/doi.org\/10.1111\/cns.13654.","journal-title":"CNS Neurosci Ther"},{"key":"4418_CR5","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1111\/cas.14927","volume":"112","author":"S Chen","year":"2021","unstructured":"Chen S, et al. Clinical use of machine learning-based pathomics signature for diagnosis and survival prediction of bladder cancer. Cancer Sci. 2021;112:2905\u201314. https:\/\/doi.org\/10.1111\/cas.14927.","journal-title":"Cancer Sci"},{"key":"4418_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.molmed.2023.10.001","volume":"30","author":"A Pandeya","year":"2024","unstructured":"Pandeya A, Kanneganti T-D. Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes. Trends Mol Med. 2024;30:74\u201388. https:\/\/doi.org\/10.1016\/j.molmed.2023.10.001.","journal-title":"Trends Mol Med"},{"key":"4418_CR7","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/j.cell.2023.05.005","volume":"186","author":"B Sundaram","year":"2023","unstructured":"Sundaram B, et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs. Cell. 2023;186:2783-2801.e2720. https:\/\/doi.org\/10.1016\/j.cell.2023.05.005.","journal-title":"Cell"},{"key":"4418_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-021-03875-8","volume":"597","author":"S Lee","year":"2021","unstructured":"Lee S, et al. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence. Nature. 2021;597:415\u20139. https:\/\/doi.org\/10.1038\/s41586-021-03875-8.","journal-title":"Nature"},{"key":"4418_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06370-2","author":"L Wang","year":"2023","unstructured":"Wang L, et al. Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases. Cell Death Disease. 2023. https:\/\/doi.org\/10.1038\/s41419-023-06370-2.","journal-title":"Cell Death Disease"},{"key":"4418_CR10","doi-asserted-by":"publisher","first-page":"22206","DOI":"10.1002\/cam4.6803","volume":"12","author":"H Cai","year":"2023","unstructured":"Cai H, Lv M, Wang T. PANoptosis in cancer, the triangle of cell death. Cancer Med. 2023;12:22206\u201323. https:\/\/doi.org\/10.1002\/cam4.6803.","journal-title":"Cancer Med"},{"key":"4418_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115696","author":"Y Xiong","year":"2023","unstructured":"Xiong Y. The emerging role of PANoptosis in cancer treatment. Biomed Pharmacother. 2023. https:\/\/doi.org\/10.1016\/j.biopha.2023.115696.","journal-title":"Biomed Pharmacother"},{"key":"4418_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cells11121885","author":"Y Rajesh","year":"2022","unstructured":"Rajesh Y, Kanneganti T-D. Innate immune cell death in neuroinflammation and alzheimer\u2019s disease. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11121885.","journal-title":"Cells"},{"key":"4418_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.60583","author":"T Ali","year":"2020","unstructured":"Ali T, Grote P. Beyond the RNA-dependent function of LncRNA genes. Elife. 2020. https:\/\/doi.org\/10.7554\/eLife.60583.","journal-title":"Elife"},{"key":"4418_CR14","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1016\/j.molcel.2022.05.027","volume":"82","author":"AB Herman","year":"2022","unstructured":"Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022;82:2252\u201366. https:\/\/doi.org\/10.1016\/j.molcel.2022.05.027.","journal-title":"Mol Cell"},{"key":"4418_CR15","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s11427-013-4553-6","volume":"56","author":"J Zhu","year":"2013","unstructured":"Zhu J, Fu H, Wu Y, Zheng X. Function of lncRNAs and approaches to lncRNA-protein interactions. Sci China Life Sci. 2013;56:876\u201385. https:\/\/doi.org\/10.1007\/s11427-013-4553-6.","journal-title":"Sci China Life Sci"},{"key":"4418_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/cac2.12108","volume":"41","author":"YT Tan","year":"2020","unstructured":"Tan YT, et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun. 2020;41:109\u201320. https:\/\/doi.org\/10.1002\/cac2.12108.","journal-title":"Cancer Commun"},{"key":"4418_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semcancer.2020.12.012","volume":"75","author":"EM McCabe","year":"2021","unstructured":"McCabe EM, Rasmussen TP. lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions. Semin Cancer Biol. 2021;75:38\u201348. https:\/\/doi.org\/10.1016\/j.semcancer.2020.12.012.","journal-title":"Semin Cancer Biol"},{"key":"4418_CR18","doi-asserted-by":"publisher","first-page":"9105","DOI":"10.1002\/jcp.27587","volume":"234","author":"X Kong","year":"2018","unstructured":"Kong X, et al. LncRNA\u2013CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215. J Cell Physiol. 2018;234:9105\u201317. https:\/\/doi.org\/10.1002\/jcp.27587.","journal-title":"J Cell Physiol"},{"key":"4418_CR19","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1111\/cas.15581","volume":"113","author":"D Fang","year":"2022","unstructured":"Fang D, et al. m6A modification\u2013mediated lncRNA TP53TG1 inhibits gastric cancer progression by regulating CIP2A stability. Cancer Sci. 2022;113:4135\u201350. https:\/\/doi.org\/10.1111\/cas.15581.","journal-title":"Cancer Sci"},{"key":"4418_CR20","doi-asserted-by":"crossref","unstructured":"Zong S, Dai W, Guo X, Wang K. LncRNA-SNHG1 promotes macrophage M2-like polarization and contributes to breast cancer growth and metastasis. 2021;13:23169-23181","DOI":"10.18632\/aging.203609"},{"key":"4418_CR21","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4049\/jimmunol.2200508","volume":"209","author":"N Pandian","year":"2022","unstructured":"Pandian N, Kanneganti T-D. PANoptosis: a unique innate immune inflammatory cell death modality. J Immunol. 2022;209:1625\u201333. https:\/\/doi.org\/10.4049\/jimmunol.2200508.","journal-title":"J Immunol"},{"key":"4418_CR22","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1016\/j.csbj.2021.07.038","volume":"19","author":"Y Wang","year":"2021","unstructured":"Wang Y, Kanneganti T-D. From pyroptosis, apoptosis and necroptosis to PANoptosis: a mechanistic compendium of programmed cell death pathways. Comput Struct Biotechnol J. 2021;19:4641\u201357. https:\/\/doi.org\/10.1016\/j.csbj.2021.07.038.","journal-title":"Comput Struct Biotechnol J"},{"key":"4418_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1254119","author":"HB Zhang","year":"2023","unstructured":"Zhang HB, Pan JY, Zhu T. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1254119.","journal-title":"Front Pharmacol"},{"key":"4418_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2025.1573480","author":"X Xiong","year":"2025","unstructured":"Xiong X, Liu W, Yao C. Development of an alkaliptosis-related lncRNA risk model and immunotherapy target analysis in lung adenocarcinoma. Front Genet. 2025. https:\/\/doi.org\/10.3389\/fgene.2025.1573480.","journal-title":"Front Genet"},{"key":"4418_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-021-07781-1","author":"R Goering","year":"2021","unstructured":"Goering R, et al. LABRAT reveals association of alternative polyadenylation with transcript localization, RNA binding protein expression, transcription speed, and cancer survival. BMC Genom. 2021. https:\/\/doi.org\/10.1186\/s12864-021-07781-1.","journal-title":"BMC Genom"},{"key":"4418_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imr.12909","volume":"297","author":"M Zheng","year":"2020","unstructured":"Zheng M, Kanneganti TD. The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis). Immunol Rev. 2020;297:26\u201338. https:\/\/doi.org\/10.1111\/imr.12909.","journal-title":"Immunol Rev"},{"key":"4418_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00238","author":"P Samir","year":"2020","unstructured":"Samir P, Malireddi RKS, Kanneganti TD. The PANoptosome: a deadly protein complex driving pyroptosis, apoptosis, and necroptosis (PANoptosis). Front Cellular Infect Microbiol. 2020. https:\/\/doi.org\/10.3389\/fcimb.2020.00238.","journal-title":"Front Cellular Infect Microbiol"},{"key":"4418_CR28","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/s0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2016;387:1540\u201350. https:\/\/doi.org\/10.1016\/s0140-6736(15)01281-7.","journal-title":"The Lancet"},{"key":"4418_CR29","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1158\/1078-0432.Ccr-09-2891","volume":"16","author":"L Zitvogel","year":"2010","unstructured":"Zitvogel L, et al. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010;16:3100\u20134. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-2891.","journal-title":"Clin Cancer Res"},{"key":"4418_CR30","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.omtn.2021.04.003","volume":"24","author":"F Xu","year":"2021","unstructured":"Xu F, Huang X, Li Y, Chen Y, Lin L. m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD. Molecular Therapy Nucleic Acids. 2021;24:780\u201391. https:\/\/doi.org\/10.1016\/j.omtn.2021.04.003.","journal-title":"Molecular Therapy Nucleic Acids"},{"key":"4418_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-022-02727-7","author":"F Wang","year":"2022","unstructured":"Wang F, Lin H, Su Q, Li C. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma. World J Surg Oncol. 2022. https:\/\/doi.org\/10.1186\/s12957-022-02727-7.","journal-title":"World J Surg Oncol"},{"key":"4418_CR32","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202009045","author":"MC Bridges","year":"2021","unstructured":"Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021. https:\/\/doi.org\/10.1083\/jcb.202009045.","journal-title":"J Cell Biol"},{"key":"4418_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01359-4","author":"T Liu","year":"2022","unstructured":"Liu T, et al. Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma. J Hematol Oncol. 2022. https:\/\/doi.org\/10.1186\/s13045-022-01359-4.","journal-title":"J Hematol Oncol"},{"key":"4418_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1120034","author":"P Zhu","year":"2023","unstructured":"Zhu P, et al. Advances in mechanism and regulation of PANoptosis: Prospects in disease treatment. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1120034.","journal-title":"Front Immunol"},{"key":"4418_CR35","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.2147\/jir.S403819","volume":"16","author":"C Shi","year":"2023","unstructured":"Shi C, et al. PANoptosis: a cell death characterized by pyroptosis, apoptosis, and necroptosis. J Inflamm Res. 2023;16:1523\u201332. https:\/\/doi.org\/10.2147\/jir.S403819.","journal-title":"J Inflamm Res"},{"key":"4418_CR36","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/imr.13279","volume":"321","author":"X Sun","year":"2023","unstructured":"Sun X, et al. PANoptosis: mechanisms, biology, and role in disease. Immunol Rev. 2023;321:246\u201362. https:\/\/doi.org\/10.1111\/imr.13279.","journal-title":"Immunol Rev"},{"key":"4418_CR37","doi-asserted-by":"publisher","unstructured":"Yan WT et al. PANoptosis-like cell death in ischemia\/reperfusion injury of retinal neurons. Neural regeneration research Publish Ahead of Print. 2023. https:\/\/doi.org\/10.4103\/1673-5374.346545.","DOI":"10.4103\/1673-5374.346545"},{"key":"4418_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111161","author":"Y-Q He","year":"2023","unstructured":"He Y-Q, et al. Ursodeoxycholic acid alleviates sepsis-induced lung injury by blocking PANoptosis via STING pathway. Int Immunopharmacol. 2023. https:\/\/doi.org\/10.1016\/j.intimp.2023.111161.","journal-title":"Int Immunopharmacol"},{"key":"4418_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.666313","author":"G Ma","year":"2021","unstructured":"Ma G, et al. The role of long noncoding RNA AL161431.1 in the development and progression of pancreatic cancer. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.666313.","journal-title":"Front Oncol"},{"key":"4418_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ncrna8030040","author":"I Iaccarino","year":"2022","unstructured":"Iaccarino I, et al. LINC00892 Is an lncRNA induced by T cell activation and expressed by follicular lymphoma-resident T helper cells. Non-Coding RNA. 2022. https:\/\/doi.org\/10.3390\/ncrna8030040.","journal-title":"Non-Coding RNA"},{"key":"4418_CR41","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1158\/1078-0432.Ccr-22-3396","volume":"29","author":"D Leng","year":"2023","unstructured":"Leng D, et al. Comprehensive analysis of tumor microenvironment reveals prognostic ceRNA network related to immune infiltration in Sarcoma. Clin Cancer Res. 2023;29:3986\u20134001. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-3396.","journal-title":"Clin Cancer Res"},{"key":"4418_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.718991","author":"X Chen","year":"2021","unstructured":"Chen X, et al. A novel assessment model based on molecular subtypes of hypoxia-related LncRNAs for prognosis of bladder cancer. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.718991.","journal-title":"Front Cell Dev Biol"},{"key":"4418_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-023-01099-0","author":"J Feng","year":"2023","unstructured":"Feng J, Yu Y, Yin W, Qian S. Development and verification of a 7-lncRNA prognostic model based on tumor immunity for patients with ovarian cancer. J Ovarian Res. 2023. https:\/\/doi.org\/10.1186\/s13048-023-01099-0.","journal-title":"J Ovarian Res"},{"key":"4418_CR44","doi-asserted-by":"publisher","first-page":"522","DOI":"10.7150\/ijbs.67556","volume":"18","author":"Z Chen","year":"2022","unstructured":"Chen Z, et al. LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1\u03b1\/ glycolysis axis in lung adenocarcinoma. Int J Biol Sci. 2022;18:522\u201335. https:\/\/doi.org\/10.7150\/ijbs.67556.","journal-title":"Int J Biol Sci"},{"key":"4418_CR45","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12558","author":"G Wang","year":"2021","unstructured":"Wang G, et al. FAM83A and FAM83A-AS1 both play oncogenic roles in lung adenocarcinoma. Oncol Lett. 2021. https:\/\/doi.org\/10.3892\/ol.2021.12558.","journal-title":"Oncol Lett"},{"key":"4418_CR46","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1080\/15384101.2019.1664225","volume":"18","author":"G Xiao","year":"2019","unstructured":"Xiao G, Wang P, Zheng X, Liu D, Sun X. FAM83A-AS1 promotes lung adenocarcinoma cell migration and invasion by targeting miR-150-5p and modifying MMP14. Cell Cycle. 2019;18:2972\u201385. https:\/\/doi.org\/10.1080\/15384101.2019.1664225.","journal-title":"Cell Cycle"},{"key":"4418_CR47","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1080\/21655979.2022.2037871","volume":"13","author":"H Huang","year":"2022","unstructured":"Huang H, et al. Long non-coding RNA FAM83A antisense RNA 1 (lncRNA FAM83A-AS1) targets microRNA-141-3p to regulate lung adenocarcinoma cell proliferation, migration, invasion, and epithelial-mesenchymal transition progression. Bioengineered. 2022;13:4964\u201377. https:\/\/doi.org\/10.1080\/21655979.2022.2037871.","journal-title":"Bioengineered"},{"key":"4418_CR48","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1080\/15384101.2023.2216507","volume":"22","author":"H Wang","year":"2023","unstructured":"Wang H, et al. LncRNA FAM83A-AS1 promotes epithelial\u2013mesenchymal transition of pancreatic cancer cells via Hippo pathway. Cell Cycle. 2023;22:1514\u201327. https:\/\/doi.org\/10.1080\/15384101.2023.2216507.","journal-title":"Cell Cycle"},{"key":"4418_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01134-6","author":"X Yin","year":"2024","unstructured":"Yin X, et al. lncRNA FLJ20021 regulates CDK1-mediated PANoptosis in a ZBP1-dependent manner to increase the sensitivity of laryngeal cancer-resistant cells to cisplatin. Discover Oncol. 2024. https:\/\/doi.org\/10.1007\/s12672-024-01134-6.","journal-title":"Discover Oncol"},{"key":"4418_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-93167-2","author":"W Zhao","year":"2025","unstructured":"Zhao W, et al. Long non-coding RNA AC133552.2: biomarker and therapeutic target in osteosarcoma via PANoptosis gene screening. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/s41598-025-93167-2.","journal-title":"Sci Rep"},{"key":"4418_CR51","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jare.2022.10.019","volume":"51","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, et al. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer. J Adv Res. 2023;51:121\u201334. https:\/\/doi.org\/10.1016\/j.jare.2022.10.019.","journal-title":"J Adv Res"},{"key":"4418_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1274937","author":"S Wu","year":"2023","unstructured":"Wu S, et al. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1274937.","journal-title":"Front Immunol"},{"key":"4418_CR53","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00432-022-03939-w","volume":"149","author":"J Eckardt","year":"2022","unstructured":"Eckardt J, et al. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. J Cancer Res Clin Oncol. 2022;149:833\u201340. https:\/\/doi.org\/10.1007\/s00432-022-03939-w.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4418_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2022","unstructured":"Hassin O, Oren M. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discovery. 2022;22:127\u201344. https:\/\/doi.org\/10.1038\/s41573-022-00571-8.","journal-title":"Nat Rev Drug Discovery"},{"key":"4418_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030512","author":"K Voskarides","year":"2023","unstructured":"Voskarides K, Giannopoulou N. The Role of TP53 in adaptation and evolution. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12030512.","journal-title":"Cells"},{"key":"4418_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02702-4","author":"F Zhou","year":"2023","unstructured":"Zhou F, et al. Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer. J Exp Clin Cancer Res. 2023. https:\/\/doi.org\/10.1186\/s13046-023-02702-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"4418_CR57","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1111\/jcmm.17866","volume":"27","author":"H Wei","year":"2023","unstructured":"Wei H, et al. Titin as a potential novel therapeutic target in colorectal cancer. J Cell Mol Med. 2023;27:2937\u201344. https:\/\/doi.org\/10.1111\/jcmm.17866.","journal-title":"J Cell Mol Med"},{"key":"4418_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.916568","author":"Z Liu","year":"2023","unstructured":"Liu Z, et al. Heterogeneous pattern of gene expression driven by TTN mutation is involved in the construction of a prognosis model of lung squamous cell carcinoma. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.916568.","journal-title":"Front Oncol"},{"key":"4418_CR59","doi-asserted-by":"publisher","DOI":"10.2174\/0113862073246841230922052004","author":"K Ying","year":"2023","unstructured":"Ying K, Zou L, Wang D, Wang R, Qian J. Co-mutation of TP53 and TTN is correlated with the efficacy of immunotherapy in lung squamous cell carcinoma. Comb Chem High Throughput Screen. 2023. https:\/\/doi.org\/10.2174\/0113862073246841230922052004.","journal-title":"Comb Chem High Throughput Screen"},{"key":"4418_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01738-6","author":"Z Liu","year":"2023","unstructured":"Liu Z, et al. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. Mol Cancer. 2023. https:\/\/doi.org\/10.1186\/s12943-023-01738-6.","journal-title":"Mol Cancer"},{"key":"4418_CR61","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.Ccr-22-3181","volume":"29","author":"RS Goodman","year":"2023","unstructured":"Goodman RS, Johnson DB, Balko JM. Corticosteroids and Cancer Immunotherapy. Clin Cancer Res. 2023;29:2580\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-3181.","journal-title":"Clin Cancer Res"},{"key":"4418_CR62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.iotech.2019.06.002","volume":"1","author":"O Nussbaumer","year":"2019","unstructured":"Nussbaumer O, Koslowski M. The emerging role of \u03b3\u03b4 T cells in cancer immunotherapy. Immuno-Oncology Technology. 2019;1:3\u201310. https:\/\/doi.org\/10.1016\/j.iotech.2019.06.002.","journal-title":"Immuno-Oncology Technology"},{"key":"4418_CR63","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","volume":"20","author":"K Yang","year":"2023","unstructured":"Yang K, Halima A, Chan TA. Antigen presentation in cancer \u2014 mechanisms and clinical implications for immunotherapy. Nat Rev Clin Oncol. 2023;20:604\u201323. https:\/\/doi.org\/10.1038\/s41571-023-00789-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"4418_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01885-w","author":"M Yi","year":"2023","unstructured":"Yi M, et al. Exploiting innate immunity for cancer immunotherapy. Mol Cancer. 2023. https:\/\/doi.org\/10.1186\/s12943-023-01885-w.","journal-title":"Mol Cancer"},{"key":"4418_CR65","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41556-021-00672-3","volume":"23","author":"G Li","year":"2021","unstructured":"Li G, et al. LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nat Cell Biol. 2021;23:526\u201337. https:\/\/doi.org\/10.1038\/s41556-021-00672-3.","journal-title":"Nat Cell Biol"},{"key":"4418_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05609-2","author":"Q Wang","year":"2023","unstructured":"Wang Q, et al. LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1\u2013TINCR-USP20-PD-L1 axis. Cell Death Disease. 2023. https:\/\/doi.org\/10.1038\/s41419-023-05609-2.","journal-title":"Cell Death Disease"},{"key":"4418_CR67","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/s41418-022-00970-9","volume":"29","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Luo M, Cui X, O\u2019Connell D, Yang Y. Long noncoding RNA NEAT1 promotes ferroptosis by modulating the miR-362-3p\/MIOX axis as a ceRNA. Cell Death Differ. 2022;29:1850\u201363. https:\/\/doi.org\/10.1038\/s41418-022-00970-9.","journal-title":"Cell Death Differ"},{"key":"4418_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.964362","author":"S Zhou","year":"2022","unstructured":"Zhou S, et al. Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis, metabolism signals and immune infiltration in lung adenocarcinoma. Front Endocrinol. 2022. https:\/\/doi.org\/10.3389\/fendo.2022.964362.","journal-title":"Front Endocrinol"},{"key":"4418_CR69","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00405","author":"Y Ba","year":"2024","unstructured":"Ba Y, et al. Pyroptosis-derived long noncoding RNA profiles reveal a novel signature for evaluating the prognosis of patients with lung adenocarcinoma. JCO Precis Oncol. 2024. https:\/\/doi.org\/10.1200\/po.23.00405.","journal-title":"JCO Precis Oncol"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-026-04418-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-04418-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-04418-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T23:28:00Z","timestamp":1787527680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13019-026-04418-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4418"],"URL":"https:\/\/doi.org\/10.1186\/s13019-026-04418-w","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent of publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"619"}}